These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20456087)

  • 1. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
    Chen L; Tian Q; Zhang M; Chen D; Gao X; Yang H; Li H; Li C; Wen J; Li Y; Tian X; Chen P
    Epilepsy Res; 2019 Aug; 154():139-143. PubMed ID: 31151073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
    Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
    Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
    Kwack DW; Kim DW
    Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Kagawa Y; Inoue Y
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1517-24. PubMed ID: 26391520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
    Mehndiratta MM; Mehndiratta P; Phul P; Garg S
    J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study.
    Woo PYM; Woo AWY; Lam SW; Ko NMW; Ho JWK; Chu ACH; Kwan MCL; Chan Y; Wong HT; Chan KY
    World Neurosurg; 2020 Dec; 144():e597-e604. PubMed ID: 32916358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions.
    Duman B; Can KC; Ağtaş-Ertan E; Erdoğan S; İlhan RS; Doğan Ö; Kumbasar H; Çamsarı UM
    Gen Hosp Psychiatry; 2019; 59():67-72. PubMed ID: 31276904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genetic variants in six candidate genes with valproic acid therapy optimization.
    Hung CC; Ho JL; Chang WL; Tai JJ; Hsieh TJ; Hsieh YW; Liou HH
    Pharmacogenomics; 2011 Aug; 12(8):1107-17. PubMed ID: 21806385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis.
    Bezinover D; Postula M; Donahue K; Bentzen B; McInerney J; Janicki PK
    Anesth Analg; 2011 Oct; 113(4):858-61. PubMed ID: 21821508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.